Johnson & Johnson misses revenue estimates as blockbuster drugs disappoint Medical Dialogues Bureau24 Jan 2020 2:02 PM ISTUS: Johnson & Johnson narrowly missed quarterly revenue estimates on Wednesday as sales of its blockbuster psoriasis medicine Stelara and cancer...
Sun Pharma to ramp up global speciality business; eyes "low-to-mid teens" growth in revenues for FY20 Medical Dialogues Bureau1 Aug 2019 10:00 AM ISTThe company is targeting key ailments like psoriasis to gradually ramp up its global speciality business, Dilip Shanghvi said adding that Sun Pharma...
Sun Pharma enters licensing agreement with CMS for arthritis drug Tildrakizumab Medical Dialogues Bureau28 Jun 2019 12:30 PM ISTThe initial tenure of the agreement between Sun Pharma and CMS shall be 15 years from the first commercial sale of Tildrakizumab in Greater China and...
Bristol-Myers to sell blockbuster Otezla for its $74 billion merger with Celgene Medical Dialogues Bureau26 Jun 2019 9:00 AM ISTBristol-Myers announced its plans to buy Celgene in a cash-and-stock deal in early January to bring together the companies that specialize in oncology...
Dr Reddys yields positive results from phase 2b study of new psoriasis drug Farhat Nasim10 Jun 2019 2:02 PM ISTThe detailed safety and efficacy data from the study would be presented in future dermatology conferences, reads Dr Reddy's (Dr Reddys) recent...
Novartis sees 2019 growth as it sheds eyecare unit, narrows focus Garima30 Jan 2019 9:00 AM ISTNovartis said sales of its Entresto heart failure medicine accelerated along with revenue from its psoriasis-and-arthritis blockbuster...
Novartis Cosentyx sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data Ruby Khatun Khatun21 Sept 2017 9:57 AM ISTBasel, September 13, 2017 - Novartis announced, first of its kind Phase III data showing Cosentyx® (secukinumab) delivered high and long-lasting skin...
